New pill could tame stubborn hives when antihistamines fail
NCT ID NCT05936567
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This phase 2 trial tested an oral drug called povorcitinib in 136 adults with chronic spontaneous urticaria (hives and itching lasting months) that standard antihistamines couldn't control. Participants took either povorcitinib or a placebo for 12 weeks to see if the drug reduced hive and itch scores. The goal is to find a new option for people whose hives don't improve with usual care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Allergy and Asthma Center of Charleston
Charleston, South Carolina, 29407, United States
-
Allergy and Asthma Consultants, Pc
Redwood City, California, 94063, United States
-
Antelope Valley Clinical Trials Lancaster Office
Palmdale, California, 93551, United States
-
Arkansas Research Trials
North Little Rock, Arkansas, 72117, United States
-
Bellingham Asthma, Allergy Immunology Clinic
Bellingham, Washington, 98225, United States
-
Cahaba Dermatology
Birmingham, Alabama, 35244, United States
-
Central Sooner Research
Oklahoma City, Oklahoma, 73170, United States
-
Centrum Alergologii Sp Z.O.O
Lublin, 20-552, Poland
-
Centrum Medyczne Pratia Katowice I
Katowice, 40-081, Poland
-
Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin
Berlin, 12200, Germany
-
Clinical Research Center of Alabama
Birmingham, Alabama, 35209, United States
-
DC-MED
Swidnica, 58-100, Poland
-
David Fivenson, Md, Dermatology, Pllc
Ann Arbor, Michigan, 48103, United States
-
Delricht Research
New Orleans, Louisiana, 70115, United States
-
Dermdox Center For Dermatology
Sugarloaf, Pennsylvania, 18249, United States
-
Etg Warszawa
Warsaw, 02-793, Poland
-
First Oc Dermatology
Fountain Valley, California, 92708, United States
-
Foothills Research Center
Scottsdale, Arizona, 85260, United States
-
Klifos - Klinische Forschung Osnabruck
Osnabrück, 49074, Germany
-
Klinika Ambroziak
Warsaw, 02-953, Poland
-
Little Rock Allergy Asthma, Pa Clinical Research Center Lraac
Little Rock, Arkansas, 72205, United States
-
Melita Medical Sp. Z O. O.
Wroclaw, 50-449, Poland
-
Mensingderma Research Gmbh
Hamburg, 22391, Germany
-
Midwest Allergy Sinus Asthma, Sc
Normal, Illinois, 61761, United States
-
Newport Native Md
Newport Beach, California, 92663, United States
-
Optimed Research Ltd
Columbus, Ohio, 43235, United States
-
Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych Administracji
Warsaw, 02-507, Poland
-
Rainey and Finklea Dermatology
San Antonio, Texas, 78212, United States
-
Revival Research Institute, Llc Troy
Troy, Michigan, 48084, United States
-
Solumed Centrum Medyczne
Poznan, 60-529, Poland
-
Specderm Poznanska
Bialystok, 15-375, Poland
-
Specjalistyczny Nzoz Alergologia Plus
Poznan, 60-693, Poland
-
The Clinical Research Center Crc, Llc
St Louis, Missouri, 63141, United States
-
Treasure Valley Medical Research
Boise, Idaho, 83706, United States
-
Universitaetsklinikum Carl Gustav Carus Tu Dresden
Dresden, 01307, Germany
-
Universitaetsklinikum Schleswig-Holstein - Campus Kiel
Kiel, 24105, Germany
-
Universitats-Hautklink Tubingen
Tübingen, 72076, Germany
-
Universitatsklinikum Frankfurt
Frankfurt, 60590, Germany
-
Universitatsklinikum Leipzig Aor
Leipzig, 04103, Germany
-
Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
Mainz, 55131, Germany
-
University Clinical Hospital
Opole, 45-401, Poland
-
Vital Prospects Clinical Research Institute, Pc Vpcri
Tulsa, Oklahoma, 74136, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
povorcitinib (oral tablet)
What this could lead to
If it works, this could provide a new treatment option for people with chronic hives that don't respond to standard antihistamines.
What could go wrong
This is an early phase 2 trial with only 136 participants, so results may not apply to everyone. The drug may not prove effective or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.